Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-08-01), Labo Euromedis's 14-Day RSI is 57.59.
The industry rank for Labo Euromedis's 14-Day RSI or its related term are showing as below:
FRA:61R's 14-Day RSI is ranked worse than 80.16% of 126
companies
in the Medical Distribution industry
Industry Median: 50.65
vs FRA:61R: 57.59
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Labo Euromedis 14-Day RSI Related Terms
FRA:61R vs MCK, COR, CAH: 14-Day RSI Comparison
For the Medical Distribution subindustry, Labo Euromedis's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Labo Euromedis 14-Day RSI vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Labo Euromedis's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Labo Euromedis's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Labo Euromedis (FRA:61R) has a 14-Day RSI of 57.59 as of Aug. 01, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Labo Euromedis and its competitors. According to the industry distribution chart, Labo Euromedis ranks #101 out of 126 companies in the Medical Distribution industry, placing it in the top 80.2%.
Is Labo Euromedis' 14-Day RSI too high?
Labo Euromedis' current 14-Day RSI is 57.59. The Medical Distribution industry median 14-Day RSI is 50.65. Labo Euromedis' value of 57.59 is 13.7% above this industry median. Based on the distribution chart, Labo Euromedis ranks #101 out of 126 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Labo Euromedis has a GF Score™ of 61/100, reflecting its overall financial health beyond just this single metric.
How does Labo Euromedis' 14-Day RSI compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Labo Euromedis ranks #101 out of 126 companies for 14-Day RSI. This places Labo Euromedis in the lower half of its industry. The industry median 14-Day RSI is 50.65. Labo Euromedis' value of 57.59 is 13.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Medical Distribution company?
The median 14-Day RSI among Medical Distribution companies is 50.65, based on 126 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Labo Euromedis's current 14-Day RSI of 57.59 is 13.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Labo Euromedis and its competitors. For the Medical Distribution industry, the median 14-Day RSI is 50.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Labo Euromedis's current 14-Day RSI is 57.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labo Euromedis stock overvalued right now?
Labo Euromedis (FRA:61R) has a current 14-Day RSI of 57.59. The stock's GF Value™ is €4.43, compared to a current price of €5.10 — trading 15.1% above its estimated fair value. The current 14-Day RSI is 57.59 and 13.7% above the Medical Distribution industry median of 50.65. Labo Euromedis' overall GF Score™ is 61/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Labo Euromedis (FRA:61R), the current 14-Day RSI is 57.59 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Labo Euromedis (FRA:61R) Overvalued in 2026?
Based on GuruFocus' analysis, Labo Euromedis stock appears to be overvalued.
The current stock price of €5.10 is trading 15.1% above its estimated GF Value™ of €4.43.
Key valuation signals for FRA:61R:
14-Day RSI: 57.59
GF Value™: €4.43 vs. price of €5.10 (15.1% above fair value)
Industry Position: 13.7% above the Medical Distribution median (#101 of 126)
No single metric tells the full story. See the FRA:61R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Labo Euromedis is engaged in medical devices. It is engaged in the design, manufacture, rental and export of medical and surgical equipment and products.
61GF Score
Get the complete analysis for FRA:61R
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:61R has been successfully added to your 
